Scientists test 'Trained' immune cells to fight tough cancers
NCT ID NCT07396090
Summary
This early-stage study is testing a new, personalized cell therapy called CAT-101 for people with advanced solid tumors that have specific KRAS gene mutations. The therapy involves taking a patient's own immune cells, training them to target the cancer, and then reinfusing them, either alone or combined with an immunotherapy drug. The main goals are to see if the treatment is safe, if it triggers an immune response against the cancer, and if it shows any early signs of helping to control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.